18,22,46,47 |
EAE |
Myelin peptide/proteins |
50 × 106 antigen-coupled splenocytes (coupled with 0.5 mg/mL peptide in the presence of ECDI). |
24-55 μg/dose |
Treatment prevented or reversed disease depending on when treatment was initiated. |
6 |
TID |
Full length bovine insulin |
NOD mice were injected i.v. with 5 × 107 insulin coupled splenocytes at numerous time points. (coupled with 0.5 mg/mL peptide in the presence of ECDI). |
Not defined |
Demonstration of disease prevention or remission, inhibition of pathogenic T cell proliferation, decreased cytokine production, and induction of anergy. |
48 |
TID |
1040-p31 peptide |
NOD.BDC2.5.Thy1.1 TCR Tg+ cells transfer into NOD/scid mice; mice received 50 × 106 antigen-coupled splenocytes (coupled with 0.5 mg/mL peptide in the presence of ECDI). |
Not defined |
Demonstration of disease prevention or remission, inhibition of pathogenic T cell proliferation, decreased cytokine production, and induction of anergy. |
23 |
Islet Transplant |
ECDI fixed allogeneic splenocytes |
1 × 108 ECDI-treated allogeneic splenocytes were transferred into streptozotocin-treated mice that received allogeneic beta-islet cells under the kidney capsule. |
Not defined |
Demonstration of indefinite survival of allogeneic islet grafts in the absence of immunosuppression |
49 |
EAT |
Thyroglobulin-coupled spleen cells |
Suppression of experimental autoimmune thyroiditis in guinea pigs. |
133 μg/dose |
Prevention of Thyroiditis in all pre-treated animals |
50 |
Uveitis |
S-antigen (S-Ag) and interphotoreceptor retinoid binding protein (IRBP) |
Injection of S-Ag or IRBP coupled to spleen cells 5 days prior to immunization with native S-Ag or IRBP, respectively. |
Protein homogenate, unknown concentration of antigens |
Prevention of Uveitis in 6/8 rats |
51 |
Neuritis |
Myelin P253-78
|
Lewis rats receive 100 μg of SP-26/CFA; treated with 20 μg/1 × 107 splenocytes and each rat received 50 × 106 coupled cells. |
Not defined |
Prevention of neuritis |